Eylea

Kodiak Sciences' stock has surged 183%, with its new eye drugs seen as direct challengers to Regeneron's blockbuster Eylea, a leading treatment for retinal conditions. The rally marks a dramatic turnaround for the biotech as investors bet its therapies could capture a share of the highly lucrative eye-disease market currently dominated by Regeneron.